China Resources Double-Crane Pharmaceutical Co.,Ltd.
Symbol: 600062.SS
SHH
23.35
CNY
Market price today
17.5971
P/E Ratio
-0.5329
PEG Ratio
24.20B
MRK Cap
0.01%
DIV Yield
China Resources Double-Crane Pharmaceutical Co.,Ltd. (600062-SS) Stock Split, History Data
Working capital analysis
In terms of working capital, China Resources Double-Crane Pharmaceutical Co.,Ltd. maintains a healthy position.
The total current assets of the company are valued at $7638486881.
This represents a growth rate of 6.609% compared to the previous year.
Breaking down the current assets, the cash and investments are worth $3216280087, exhibiting a growth rate of 22.280% year-on-year.
The receivables, another significant portion of the current assets, are valued at $2403499872.
The year-on-year growth rate for receivables is 1.724%.
The inventory, which forms a critical part of the assets, is valued at $1562447083.
This represents a healthy year-on-year growth of -16.830%
On the liabilities side, the company's current liabilities total $3162113459.
This reflects a growth rate of 4.990% over the previous year, indicating the company's financial obligations are well under control.
2023
2022
2021
2020
2019
2018
Cash and investments
3216.28
2630.25
2834.04
2410.28
1843.91
1097.02
Receavebles
2403.50
2362.77
2127.04
2216.72
2130.91
2017.48
Inventory
1562.45
1878.63
1665.46
1289.29
1146.03
973.61
Other
215.52
92.83
92.47
32.03
159.71
168.42
Total Current Assets
7638.49
7164.96
7522.58
6800.27
6038.71
5135.22
Acc Payable
696.69
744.52
847.40
848.05
690.76
547.29
Short Term Debt
432.93
32.06
29.47
6.63
64.86
74.96
Other Current Liab
1822.29
2042.28
57.20
43.91
43.91
1352.18
Current Liabilities
3162.11
3011.83
2730.94
2670.03
2341.45
2128.00
Capital Structure
When examining the capital structure of China Resources Double-Crane Pharmaceutical Co.,Ltd., it is clear that the company manages a robust portfolio.
These earnings represent the profits that China Resources Double-Crane Pharmaceutical Co.,Ltd. has chosen to reinvest in the business rather than distribute as dividends.
